Kayla O'TOole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kayla O'TOole has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Sheri L. Holmen
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
45 shared publications - Martin McMahon
Huntsman Cancer Institute
44 shared publications - Matthew W. VanBrocklin
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
43 shared publications - Mona Foth
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
43 shared publications - Brandon Murphy
Huntsman Cancer Institute 1 Salt Lake City, Utah
26 shared publications - Amanda Jiang
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, USA
25 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
DNA primers used for PCR or Sanger seq.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
DNA primers used for PCR or Sanger seq.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Quantitative PCR (qPCR) primers used on gDNA.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Quantitative PCR (qPCR) primers used on gDNA.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Patient-derived xenografts (PDXs).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Patient-derived xenografts (PDXs).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
CRISPR guideRNAs and associated primers.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
CRISPR guideRNAs and associated primers.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Myr-dPH-AKT1:ER, Pten CRISPR, RAC1-P29S-eGFP.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Myr-dPH-AKT1:ER, Pten CRISPR, RAC1-P29S-eGFP.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Schematic of GEMM alleles and Cre initiation schedules, IHC, and immunoblotting on GEMM tumors.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Schematic of GEMM alleles and Cre initiation schedules, IHC, and immunoblotting on GEMM tumors.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Cell confluency or cytotoxicity assays, immunoblot analysis of O.10 and Mel-9.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Cell confluency or cytotoxicity assays, immunoblot analysis of O.10 and Mel-9.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Supplementary Table S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Supplementary Table S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Supplementary Table S11 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Supplementary Table S11 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Additional CYPA M136R, MEK1 P124L K57N Q56P.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma
Additional CYPA M136R, MEK1 P124L K57N Q56P.